APA (7th ed.) Citation

N, B. K., R, M., LS, J., V, Z., M, K., F, A., . . . FP, R. (2026). Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC. JHEP reports : innovation in hepatology, 8(6), 101818. https://doi.org/10.1016/j.jhepr.2026.101818

Chicago Style (17th ed.) Citation

N, Ben Khaled, et al. "Multicenter Study of Bleeding and Thromboembolic Events with Durvalumab Tremelimumab Vs. Atezolizumab and Bevacizumab in Advanced HCC." JHEP Reports : Innovation in Hepatology 8, no. 6 (2026): 101818. https://doi.org/10.1016/j.jhepr.2026.101818.

MLA (9th ed.) Citation

N, Ben Khaled, et al. "Multicenter Study of Bleeding and Thromboembolic Events with Durvalumab Tremelimumab Vs. Atezolizumab and Bevacizumab in Advanced HCC." JHEP Reports : Innovation in Hepatology, vol. 8, no. 6, 2026, p. 101818, https://doi.org/10.1016/j.jhepr.2026.101818.